<DOC>
	<DOC>NCT01133210</DOC>
	<brief_summary>The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation</brief_summary>
	<brief_title>Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)</brief_title>
	<detailed_description>The purpose of this study is to determine, in obese insulin resistant subjects, the effect of maraviroc therapy, a selective antagonist of the human chemokine receptor CCR5, on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>obese (body mass index (BMI) between 30 and 45.9) increased plasma triglyceride concentrations (150400 mg/dL) active or previous infection with hepatitis B or C history of alcohol abuse current alcohol consumption (&gt;20g/day) severe hypertriglyceridemia (&gt;400 mg/dL) active peptic ulcer disease diabetes pregnant or lactating take statins, fibrates, niacin, moderate to strong Cyp3A4 inhibitors or inducers, or any other medication that might confound interpretation of the study results will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>triglyceride</keyword>
	<keyword>cholesterol</keyword>
	<keyword>Maraviroc</keyword>
</DOC>